The FDA has designated Precision BioSciences’ (NASDAQ:DTIL) CAR-T candidate PBCAR0191 for Fast Track review for the treatment of advanced B-cell precursor acute lymphoblastic leukemia (B-ALL).
Fast Track status provides for more frequent interaction with the FDA review team and a rolling review of the marketing application.
A Phase 1/2a clinical trial is in process.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.